Open-House non-exclusive rebate agreement for Sultamicillin
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Sultamicillin (ATC-Code nach WHO: J01CR04)
Opportunity Score
Why this score?
Opportunity
52 / 100
Complexity
58 / 100
Risk factors
The participation documents are not fully available in the extracted text; key instructions are said to be in 'Anschrei...
Demand and purchase volume are explicitly unknown, and minimum quantities are not guaranteed.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Feb 29, 2028
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Feb 2028
- Non-exclusive rebate agreement for pharmaceutical products containing Sultamicillin (ATC J01CR04).
- Open-House participation model with contract conclusion available to all interested pharmaceutical companies meeting the conditions.
Show full summary
This is an Open-House framework-style pharmaceutical supply arrangement for Sultamicillin (CPV 33600000) led by AOK PLUS. It is non-exclusive, open to all interested pharmaceutical companies that meet the stated participation conditions, with no individual negotiations and no guaranteed minimum purchase volume. Participation documents are available via DTVP, but the extracted procurement documents themselves were not provided for analysis beyond the XML notice text. Submission is electronic via the portal communication function, not via the bidder tool, and the first participation deadline is 2026-02-03; the arrangement ends no later than 2028-02-29.
Risks
The participation documents are not fully available in the extracted text; key instructions are said to be in 'Anschrei...
Demand and purchase volume are explicitly unknown, and minimum quantities are not guaranteed.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Applicant must be a pharmaceutical undertaking within the meaning of Section 4(18) AMG for the offered medicinal product.
Administrative
- Participation documents must be submitted as specified in the documents 'Anschreiben' and 'Erläuterungen der Vertragsbedingungen'.
- An 'Eigenerklärung zum Nichtvorliegen von Ausschlussgründen' must be completed and submitted.
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Open-House non-exclusive rebate agreement for Sultamicillin
Supply arrangement for non-exclusive pharmaceutical rebate agreements under Section 130a(8) SGB V for the active ingredient Sultamicillin (ATC J01CR04). The lot is an Open-House model: any interested pharmaceutical company may participate if it meets and accepts the stated conditions. No exclusivity, no individual negotiations, and no guaranteed minimum purchase volume are stated. Place of performance is Dresden, Germany, with performance covering Saxony and Thuringia as stated in the notice text.
Location
Duration
Category
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Sultamicillin (ATC-Code nach WHO: J01CR04)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 18 Dec 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 845306-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
52 / 100
Complexity
58 / 100
Risk factors
The participation documents are not fully available in the extracted text; key instructions are said to be in 'Anschrei...
Demand and purchase volume are explicitly unknown, and minimum quantities are not guaranteed.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications